L002

08/19

ALTERNATE NAMES: [(3,5-dimethyl-4-oxocyclohexa-2,5-dien-1-ylidene)amino] 4-methoxybenzenesulfonate; 4-(4-methoxyphenylsulfonyloxyimino)-2,6-dimethylcyclohexa-2,5-dienone; (3,5-dimethyl-4-oxocyclohexa-2,5-dien-1-ylidene)amino 4-methoxybenzene-1-sulfonate; (3,5-dimethyl-4-oxocyclohexa-2,5-dienylidene)azamethyl 4-methoxybenzenesulfonate; 2,6-dimethyl-2,5-cyclohexadiene-1,4-dione 4-[O-[(4-methoxyphenyl)sulfonyl]oxime]; NSC764414; p300/CBP Inhibitor VI

CATALOG #:
B2859-1 1 mg
B2859-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: $C_{15}H_{15}NO_5S$

MOLECULAR WEIGHT: 321.35

CAS NUMBER: 321695-57-2

APPEARANCE: A crystalline solid

PURITY: ≥98%

SOLUBILITY:
~1 mg/ml in ethanol
~30 mg/ml in DMSO and DMF

DESCRIPTION: L002 is an inhibitor of p300 histone acetyltransferase (KAT3B). It shows an IC_{50} of 1.98 µM against p300 *in vitro*. It inhibits acetylation of histones, p53 and suppresses STAT3 activation. It is cytotoxic to breast cancer cell lines, especially those derived from triple-negative breast cancer cells. It potently suppresses tumor growth and histone acetylation of MDA-MB-468 xenografts.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Yang, H., Pinello, C.E., Luo, J., et al. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Molecular Cancer Therapeutics 12(5), 610-620 (2013).

RELATED PRODUCTS:

Butyrolactone 3 (Cat. No. B2817)
Garcinol (Cat. No. 2088)
C646, p300/CBP Inhibitor (Cat. No. 1948)
Anacardic Acid (Cat. No. 1849)
EML-425 (B1882)

DISCLAIMER: ***FOR RESEARCH USE ONLY! Not to be used on humans.***